Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Diabetes
Interventions: Tailored Patient Intervention, Patient-physician intervention, Patient and PCP intervention with analyzed data; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PTSD, Alcohol Abuse, Alcoholism
Interventions: Topiramate, Placebo administration; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Hepatitis B
Interventions: TDF, ADV, TDF placebo, ADV placebo, FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 17
States / cities: La Jolla, California • Pasadena, California • San Diego, California + 12 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Multiple Sclerosis, Hypertension
Interventions: Home-based aerobic training; Behavioral
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: B/F/TAF, GS-3242, Lenacapavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Ft. Pierce, Florida • Houston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 39
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more

Conditions: Polycystic Ovary Syndrome, PCOS, Infertility
Interventions: Letrozole, Clomiphene Citrate; Drug
Lead sponsor: Rachel Mejia; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Davenport, Iowa • Iowa City, Iowa • West Des Moines, Iowa + 1 more

Conditions: Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions: Six Step Model of Self-Forgiveness, Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: McKeesport, Pennsylvania

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation; Drug · Radiation
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 6 Months to 15 Years
Enrollment: 11,837 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 90
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more

Conditions: Healthy
Interventions: Fenobam, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Rhinosinusitis
Interventions: Etokimab, Placebo, Mometasone Furoate Nasal Spray; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Little Rock, Arkansas • Canoga Park, California • Roseville, California + 24 more

Conditions: HIV Infections
Interventions: GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Substance-Related Disorders
Interventions: Letters; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus
Interventions: Exubera, Randomized diabetes therapy; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 7,439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 131
States / cities: Bay Minette, Alabama • Graysville, Alabama • Pell City, Alabama + 111 more

Conditions: Pain
Interventions: EXPAREL, Ketorolac, laparoscopic abdominal hernia repair, an open surgery for abdominal hernia repair; Drug · Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ischemic Stroke, Intracranial Hemorrhage, Transient Ischemic Attack
Interventions: stroke education; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Haemophilia A, Haemophilia A With Inhibitors
Interventions: NNC0365-3769 (Mim8); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 34
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more

Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Interventions: Alintegimod, Ipilimumab, Nivolumab; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more

Conditions: Hyperkalemia
Interventions: Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin, Glucose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Montgomery, Alabama • Phoenix, Arizona • Detroit, Michigan + 7 more

Conditions: Total Knee Arthroplasty
Interventions: Methylprednisolone, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Oak Brook, Illinois

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention C Daridorexant, Intervention C Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Lung Diseases, Tuberculosis
Interventions: Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm); Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Mobile Diabetes Management

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

Behavioral Insights to Encourage Judicious Prescribing of Opioids

Follow-Up Study for Exubera

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

Stroke Education Intervention Trial - Pilot

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Medrol Dosepak for Outpatient Total Knee Arthroplasty

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents